Fig. 4From: SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021Neutralisation of viral variants using the sera from the first and second epidemic waves. Anti-RBD seropositive sera from the SARS-CoV-2 epidemic waves 1 and 2 were subjected to a SARS-CoV-2 pseudovirus neutralisation assay. A Correlation of SARS-CoV-2 antibody neutralisation potency against D614G WT and beta variant. B Proportion of wave 1 or wave 2 sera with neutralisation activity against D614G WT or beta variant. The threshold of detection for the neutralisation assay is ID50 > 20. RBD, receptor-binding domainBack to article page